Ibogaine is gaining global attention as a potential breakthrough in mental health and addiction treatment. Yet despite increasing interest and promising results, it remains unavailable in the United States.
This raises an important question: why?
In the United States, ibogaine is classified as a Schedule I substance.
This means it is considered to have:
This classification severely limits both research and access.
Regulatory bodies such as the U.S. Food and Drug Administration require extensive clinical trials before any substance can be approved for medical use.
One of the main reasons for these restrictions is safety.
Ibogaine is a powerful substance that can have serious physical effects if not used correctly. Concerns around heart-related risks have slowed down research efforts in the past.
Without sufficient large-scale studies, regulators remain cautious.
Despite these challenges, attitudes are beginning to shift.
Recent initiatives supported by Donald Trump aim to accelerate research into psychedelic therapies.
This could eventually lead to:
However, these changes are still in early stages.
Because ibogaine treatment is not available in the U.S., many individuals choose to travel abroad.
Mexico has become one of the most popular destinations due to:
For many, this is currently the only way to access ibogaine therapy safely.
Not all treatment centers are the same.
When considering ibogaine treatment, it is essential to choose a provider that offers:
This ensures both safety and effectiveness.
As research progresses, ibogaine may eventually become available in the United States.
Until then, individuals seeking treatment must explore international options.
Iboga World connects you with trusted ibogaine treatment providers in Mexico.
👉 All contact and inquiries go through Iboga World:
https://ibogaworld.com/contact